US Public Health Spending on Biosimilars: A Data Driven Analysis

This report provides a comprehensive analysis of the impact of biosimilars on US public health spending, specifically focusing on Medicare and Medicaid. It delves into the dynamics of biosimilar approvals, launches and uptake, offering insights into how these factors influence pharmaceutical expenditure. By examining data from the Centers for Medicare and Medicaid Services (CMS) and the FDA, the report evaluates the cost effectiveness of biosimilars compared to originator biologics, highlighting price differences and revenue achievements of biosimilar manufacturers.

Additionally, it explores the implications of biosimilar prescribing on patient access and healthcare costs, providing a forward-looking perspective on the potential market shifts as more biologic patents expire. This analysis is essential for pharmaceutical professionals seeking to understand the evolving landscape of biosimilars within the US public health system.

Key Questions Answered:

• 1. How have biosimilars impacted pharmaceutical expenditure under Medicare and Medicaid?
• 2. What is the current level of biosimilar uptake in the US public health system?
• 3. How do biosimilar and originator product prices compare within Medicare and Medicaid?
• 4. Which biosimilar manufacturers have achieved the greatest revenues in the public reimbursement system?
• 5. What is the effect of biosimilar prescribing on reducing expenditure for biologic products?
• 6. How has the availability of biosimilars influenced patient numbers under Medicare and Medicaid?
• 7. What are the key metrics used to assess biosimilar performance in the US public health system?
• 8. How do Medicare Part B and Part D differ in terms of biosimilar reimbursement?
• 9. What is the projected impact of newer biosimilars as more biologic patents expire?
• 10. How does the report utilise CMS data to evaluate biosimilar uptake and expenditure?

Key Companies:

Methodology:

Dossier reports are developed from independent and concise analysis derived from original industry surveys and in-depth interviews with industry thought leaders. Reports analyse in detail significant developments and market trends that pharma executives need to understand if they are to manage the opportunities and challenges that lie ahead. The focus of each report is defined by a review of the secondary literature and any knowledge gaps identified. Based on this initial research, an evidence-based and expert-informed discussion guide is developed to ensure the research answers the most critical questions. Additionally, robust screening criteria are established to ensure that those interviewed are qualified in terms of their experience, knowledge and stature to speak on the topic.

What makes our reports different?

FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.